Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial

J. S. Tronieri; T. A. Wadden; O. A. Walsh; R. I. Berkowitz; N. Alamuddin; K. Gruber; S. Leonard; A. M. Chao Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial Metabolism

Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation

L. A. Powell; P. Crowe; C. Kankara; J. McPeake; D. R. McCance; I. S. Young; E. R. Trimble; A. McGinty Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation Clinical science
Insulin Resistance & Diabetes

The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study

L. Patterson; F. Kee; C. Hughes; D. O'Reilly The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study BMC Public Health

Prescribing for weight loss in primary care: evidence from a population based study

L. Patterson; C. Patterson; F. Kee; C. Hughes; M. Donnelly; D. O'Reilly Prescribing for weight loss in primary care: evidence from a population based study J Epidemiol Community Health

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

X. Pi-Sunyer; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; D. C. Lau; C. W. le Roux; R. Violante Ortiz; C. B. Jensen; J. P. Wilding A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

W. D. Porter; P. R. Flatt; C. Hölscher; V. A. Gault Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice International Journal of Obesity
Insulin Resistance & Diabetes

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

V. Pathak; P. R. Flatt; N. Irwin Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

Liraglutide: another reason to target prediabetes?

C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Insulin Resistance & Diabetes

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial

D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Insulin Resistance & Diabetes

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page18 Page19 Page20 … Page27 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI